Physician profile
Aman Ali
NPI 1679753164
$20,996.71
in general payments reported to CMS, 2019-2025
26 companies · $4,954 in 2025
The $4,954 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,308 · 2020: $1,800 · 2021: $2,521 · 2022: $518 · 2023: $1,401 · 2024: $2,496 · 2025: $4,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,514 · Food and Beverage: $4,075 · Entertainment: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,514.08 |
| Food and Beverage | $4,075.36 |
| Entertainment | $260.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,027.95 | 2019 | |
| Edwards Lifesciences Corporation | $3,722.83 | 2019-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Abbott Laboratories | $3,420.53 | 2019-2025 | Triclip, Cardiomems |
| Boston Scientific Corporation | $2,767.15 | 2019-2025 | General - Therapies, Watchman Access System, Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $1,320.00 | 2021 | |
| Abbvie INC. | $1,050.00 | 2021 | |
| Heartflow, INC. | $837.82 | 2019-2025 | Ffrct |
| Opsens INC. | $409.18 | 2022-2023 | Optowire |
| Medtronic, INC. | $212.40 | 2022-2024 | Corevalve Evolut R, Signia |
| Amgen INC. | $160.96 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $144.80 | 2019-2024 | Camzyos, Eliquis |
| Atricure, INC. | $144.48 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Impulse Dynamics (USA) INC. | $141.87 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals Lp | $119.17 | 2022-2025 | Wainua, Farxiga |
| Pfizer INC. | $117.03 | 2023-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $105.78 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $64.73 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $48.60 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $35.34 | 2023-2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $33.94 | 2023 | Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.50 | 2024-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $20.62 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $18.48 | 2019 | |
| Scpharmaceuticals INC. | $17.67 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.95 | 2023 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.